Yana Debie, Lise Verbruggen, Marc Peeters, Peter A van Dam, Timon Vandamme
{"title":"与病毒载体疫苗相比，mRNA COVID-19疫苗在癌症患者中诱导更高的IgA滴度：对免疫策略的影响","authors":"Yana Debie, Lise Verbruggen, Marc Peeters, Peter A van Dam, Timon Vandamme","doi":"10.1016/j.ijid.2025.107939","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>IgA antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection prone cancer patients. This might be particularly relevant for cancer patients as they mount reduced IgG antibody titers after dual-dose BNT162b2 COVID-19 vaccination and even lower responses after double-dose ChAdOx1 vaccination, compared to healthy individuals. However, data on vaccine-induced IgA antibodies are scarce, especially in cancer patients.</p><p><strong>Methods: </strong>This study compares SARS-CoV-2 anti-S1 IgA antibodies after dual-dose BNT162b2 vs ChAdOx1 vaccination in cancer patients. SARS-CoV-2 anti-S1 IgA antibodies were quantified in serum samples collected 7 days after second vaccination dose (N=213) (IEQ-CoVS1RBD-IgA-1-RB ELISA kit, RayBiotech) and analyzed with colorimetric detection. Additionally correlations with different aspects of humoral immunity were assessed (neutralizing and IgG antibodies).</p><p><strong>Results: </strong>Significant lower anti-S1 IgA antibody titers were reported in cancer patients after dual-dose ChAdOx1 compared to BNT162b2 vaccination. Moreover, cancer patients that received dual-dose BNT162b2 vaccination had a significant 16.44 fold increased chance to mount detectable IgA antibodies compared to patients receiving ChAdOx1 vaccination.</p><p><strong>Conclusion: </strong>These findings highlight the potential role of boosters or alternative strategies to sustain mucosal immunity.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"107939"},"PeriodicalIF":4.8000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"mRNA COVID-19 vaccines induce superior IgA titers in cancer patients compared to viral vector vaccines: Implications for immunization strategies.\",\"authors\":\"Yana Debie, Lise Verbruggen, Marc Peeters, Peter A van Dam, Timon Vandamme\",\"doi\":\"10.1016/j.ijid.2025.107939\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>IgA antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection prone cancer patients. This might be particularly relevant for cancer patients as they mount reduced IgG antibody titers after dual-dose BNT162b2 COVID-19 vaccination and even lower responses after double-dose ChAdOx1 vaccination, compared to healthy individuals. However, data on vaccine-induced IgA antibodies are scarce, especially in cancer patients.</p><p><strong>Methods: </strong>This study compares SARS-CoV-2 anti-S1 IgA antibodies after dual-dose BNT162b2 vs ChAdOx1 vaccination in cancer patients. SARS-CoV-2 anti-S1 IgA antibodies were quantified in serum samples collected 7 days after second vaccination dose (N=213) (IEQ-CoVS1RBD-IgA-1-RB ELISA kit, RayBiotech) and analyzed with colorimetric detection. Additionally correlations with different aspects of humoral immunity were assessed (neutralizing and IgG antibodies).</p><p><strong>Results: </strong>Significant lower anti-S1 IgA antibody titers were reported in cancer patients after dual-dose ChAdOx1 compared to BNT162b2 vaccination. Moreover, cancer patients that received dual-dose BNT162b2 vaccination had a significant 16.44 fold increased chance to mount detectable IgA antibodies compared to patients receiving ChAdOx1 vaccination.</p><p><strong>Conclusion: </strong>These findings highlight the potential role of boosters or alternative strategies to sustain mucosal immunity.</p>\",\"PeriodicalId\":14006,\"journal\":{\"name\":\"International Journal of Infectious Diseases\",\"volume\":\" \",\"pages\":\"107939\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijid.2025.107939\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijid.2025.107939","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
mRNA COVID-19 vaccines induce superior IgA titers in cancer patients compared to viral vector vaccines: Implications for immunization strategies.
Objectives: IgA antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection prone cancer patients. This might be particularly relevant for cancer patients as they mount reduced IgG antibody titers after dual-dose BNT162b2 COVID-19 vaccination and even lower responses after double-dose ChAdOx1 vaccination, compared to healthy individuals. However, data on vaccine-induced IgA antibodies are scarce, especially in cancer patients.
Methods: This study compares SARS-CoV-2 anti-S1 IgA antibodies after dual-dose BNT162b2 vs ChAdOx1 vaccination in cancer patients. SARS-CoV-2 anti-S1 IgA antibodies were quantified in serum samples collected 7 days after second vaccination dose (N=213) (IEQ-CoVS1RBD-IgA-1-RB ELISA kit, RayBiotech) and analyzed with colorimetric detection. Additionally correlations with different aspects of humoral immunity were assessed (neutralizing and IgG antibodies).
Results: Significant lower anti-S1 IgA antibody titers were reported in cancer patients after dual-dose ChAdOx1 compared to BNT162b2 vaccination. Moreover, cancer patients that received dual-dose BNT162b2 vaccination had a significant 16.44 fold increased chance to mount detectable IgA antibodies compared to patients receiving ChAdOx1 vaccination.
Conclusion: These findings highlight the potential role of boosters or alternative strategies to sustain mucosal immunity.
期刊介绍：
International Journal of Infectious Diseases (IJID)
Publisher: International Society for Infectious Diseases
Publication Frequency: Monthly
Type: Peer-reviewed, Open Access
Scope:
Publishes original clinical and laboratory-based research.
Reports clinical trials, reviews, and some case reports.
Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases.
Emphasizes diseases common in under-resourced countries.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
